USFDA concludes audit at Cohance Lifesciences Jaggaiahpet facility
Hyderabad: Cohance Lifesciences has announced that the United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at our API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh.
The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero Form 483 observations.
"We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets," the company stated in a BSE filing.
Read also: Cohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ Bio
Cohance Lifesciences is a technology-driven CDMO, providing integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators. The company has over 100 active projects and a pipeline of late-stage molecules.
